Navigation Links
Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
Date:4/26/2009

study. Relapse rates between these two arms also were not significantly different (32.7 percent (16/49) vs. 47.1 percent (32/68), respectively) and adverse events were similar among treatment groups (secondary endpoints). Early discontinuation rates were higher in the 72-week arm compared to the 48-week arm (23.3 percent (17/73) vs. 9.3 percent (8/86), respectively).

Reduced Dose and Duration of Peginterferon Alfa-2b + Weight-Based Ribavirin in European and Asian Genotype 2 and 3 Chronic Hepatitis C Patients (REDD 2/3 Trial)(4)

Shorter duration treatment of patients chronically infected with HCV genotype 2 or 3 (G2/3) with peginterferon and ribavirin has been largely unsuccessful compared with standard-duration treatment (24 weeks). The implications of a reduced peginterferon dose in G2/3 patients were unknown. The primary objective of the REDD 2/3 study was to evaluate the effect of reduced treatment duration or a reduced PEGINTRON dose on SVR and relapse rates among treatment-naive G2/3 patients in an international, multicenter, non-inferiority study. The study began as a real-world, investigator-initiated study conducted in Germany and then the patient population was expanded to include centers in Europe and Asia-Pacific. In total, 682 patients were treated. Of these, 80.2 percent were G3 and 53.1 percent had high baseline viral load (greater than or equal to 600,000 IU/mL), both negative factors for achieving SVR.

Eligible patients were randomized to one of three arms: (A) PEGINTRON (1.5 mcg/kg/wk) for 24 weeks (approved dose), (B) PEGINTRON (1.0 mcg/kg/wk) for 24 weeks (low dose) or (C) PEGINTRON (1.5 mcg/kg/wk) for 16 weeks (short duration), each in combination with weight-based REBETOL (800-1200 mg/day). Co-primary end points were non-inferiority between arms A and B and A and C. SVR rates overall were (A) 66.5 percent (153/230), (B) 64.3 percent (144/224) and (C) 56.6 percent (129/228). Neither
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
4. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
8. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/x5lz9r/global_poc ... POC Diagnostics Market 2015-2019" report to their offering. ... POC Diagnostics market to grow at a CAGR of ... POC diagnostics are IVD devices and tools used for ... The use of these devices helps in the rapid ...
(Date:3/3/2015)...  Columbia Laboratories, Inc. (Nasdaq: CBRX ) ... specialty pharmaceutical company focused on pharmaceuticals for women,s health, ... Annual ROTH Conference, which will take place from March ... Dana Point, California . Management,s presentation will take ... Time (12:00 p.m. Eastern Time) in the Promenade room. ...
(Date:3/3/2015)... 03, 2015 Research and Markets ... the "Global Ultrasound Equipment Market 2015-2019" ... The Global Ultrasound Equipment market to grow ... 2014-2019 Ultrasound equipment are used to ... are extensively used by cardiologists, radiologists, surgeons, obstetricians, ...
Breaking Medicine Technology:Global POC Diagnostics Market 2015-2019 with Abbott Labs, Alere, Bayer Healthcare, Danaher, F. Hoffmann-La Roche & Johnson & Johnson Dominating 2Global Ultrasound Equipment Market 2015-2019: Rise in Number of MI Diagnostic Procedures with GE Healthcare, Phillips Healthcare, Siemens Healthcare & Toshiba Medical Systems Dominating 2
... Sept. 2, 2011 The overall success of ... markets sector. Access to formularies and relationships with ... growth for pharmaceutical organizations. Given the importance of ... account executives, performance is a critical undertaking for ...
... Cox Business have partnered to make a new, diagnostically ... the Valley and across the state at the same ... first dedicated outpatient offering of breast tomosynthesis in Arizona ... Sub-specialty trained radiologists at SimonMed can now ...
Cached Medicine Technology:Assessing the Performance of Account Executives for the Critical Managed Markets Sector 2SimonMed and Cox Business Bring Breast Tomosynthesis to Arizona 2
(Date:3/3/2015)... Il. (PRWEB) March 03, 2015 The ... is set to reveal the world’s first fully integrated ... are breathing and controls an air purifier to remove ... user informed, and in control, via phone, tablet or ... purifiers in over 50 countries worldwide, will unveil its ...
(Date:3/3/2015)... UK (PRWEB) March 03, 2015 The ... growth of the augmentation market. The wearable augmentation sector ... terms of size in the upcoming years. , ... market owing to a big number of new products ... North American region, high technological advancements as well as ...
(Date:3/3/2015)... Daylight Savings Time may lead to your ... tips for parents. , Parents and their children may feel ... when they set their clocks forward one hour for Daylight ... -- one hour earlier -- you will have already lost ... thinking about “sleep hygiene” for their kids and teens this ...
(Date:3/3/2015)... Sunday, March 1, through Saturday, March 7, is ... year, every region of the country is at risk for ... Insurance is sharing the following tips from the Centers ... you safe in the event of severe weather: , Winter ... frequently to prevent loss of body heat. Wear warm, loose-fitting, ...
(Date:3/3/2015)... — (PRWEB) March 03, 2015 -- vRad ... and radiology practice, today announced that Arlene Sussman, MD, ... will host a live webinar to explore how telemedicine ... specialized breast imaging services for women virtually anywhere. Click ... Breast Imaging Service Line” on March 4, 2015 at ...
Breaking Medicine News(10 mins):Health News:Smart sensor and air purifier interconnect to track and trap dust, pollen and dangerous particles in home and workplace air 2Health News:Human Augmentation Market to Pose 43.5% CAGR Through 2020, States MarketsandMarkets in its New Research Study Now Available at MarketPublishers.com 2Health News:Don’t Let Daylight Savings Disrupt Your Child’s Sleep 2Health News:Amica Insurance Has Tips for National Severe Weather Preparedness Week 2Health News:Latest vRad Webinar: Building World-Class Breast Imaging Services Virtually Anywhere with Telemedicine Best Practices 2Health News:Latest vRad Webinar: Building World-Class Breast Imaging Services Virtually Anywhere with Telemedicine Best Practices 3Health News:Latest vRad Webinar: Building World-Class Breast Imaging Services Virtually Anywhere with Telemedicine Best Practices 4
Medtronic, Inc., a world leader in therapies for restoring people with chronic conditions to full life, introduces the AT500 Pacing System for the management of atrial tachyarrhythmias and bradycardi...
The first-ever pacemaker to include Managed Ventricular Pacing (MVP), the EnRhythm Pacing System promotes intrinsic conduction and is clinically proven to significantly reduce unnecessary right ventr...
... 3000Dx (GCS3000Dx) is the first microarray instrumentation ... consists of the FS450Dx Fluidics Station which ... array, the GCS3000Dx Scanner with AutoLoader Dx ... to be scanned without operator intervention, and ...
... compact system capable of B-mode, M-mode, ... intuitive operation, high mobility, and exceptional ... incorporates an alphanumeric keyboard, several one-touch ... toggle keys for application specific functions. ...
Medicine Products: